Table of Contents Table of Contents
Previous Page  735 / 812 Next Page
Information
Show Menu
Previous Page 735 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S731

(DUP) has been described as an important predictor of outcome

in FEP [2].

Aims

With this study, we want to know which baseline charac-

teristics and clinical outcomes differ between FEP patients with and

without substance use.

Methods

One hundred and seventy-five FEP were consecutively

admitted to Hospital del Mar since January 2008 to September 2014

and entered the FEP programme of the institution. The included

evaluationwas socio-demographic and clinical data at baseline and

1 year follow-up. We studied differences in age, gender, DUP, GAF

scores at baseline and 1 year follow-up and PANSS subscale scores

at base and 1 year follow-up between substance users and non-

users.

Results

Cannabis: we found that users were significative younger

(

P

< 0.01), had a higher proportion of males (

P

< 0.01) and a signi-

ficative shorter DUP in users (

P

= 0.008).

Alcohol: we found that users were significative younger (

P

< 0.009),

had a higher proportion of males (

P

< 0.003) and a significative

lower PANNS negative scores at baseline (

P

= 0.01) and 1 year

follow-up (

P

= 0.03).

Conclusions

In our sample of first episode psychosis, cannabis

and alcohol use is linked with a younger age and a high proportion

of males. Moreover, it seems that cannabis use could be associated

with a shorter DUP.

References not available.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2180

EV1196

Factors associated with schizophrenic

evolution after a first episode

psychosis

M. Turki

, N.

Halouani , R. Naoui , I. Gassara , N. Hamza ,

J. Aloulou , O. Amami

Hédi Chaker university hospital, psychiatry department, Sfax, Tunisia

Corresponding author.

Introduction

The evolution of a first episode psychosis is a fun-

damental question, despite its unpredictability. It affects the type

of management and drug treatment. In this context, schizophre-

nia, a disabling psychiatric disease, remains the most formidable

evolution.

Objective

Assess the frequency and factors associated with

schizophrenic evolution after a first episode psychosis.

Methods

We conducted a retrospective, descriptive and analytic

study including 55 patients hospitalized in psychiatry department,

Hédi Chaker Hospital, Sfax, Tunisia, during 7 years (from 2007 to

2013), then managed in the outpatient department. We collected

socio-demographic, clinical and evolutive data from clinical obser-

vations.

Results

The mean age was 26.5 years. Sex ratio (M/F) was 2.9.

Among our patients, 74.5%were single and 49.1% had no profession.

A trigger factor of this episode was noted in 43.6% and a break with

the previous functioning in 63.6% of cases. A schizoid personality

was reported in 74.5% of the population. All patients presented pos-

itive symptoms, 96.4% had negative symptoms and 61.8% presented

mood symptoms.

Schizophrenic evolution was reported in 38.2% of patients. Factors

associated with this evolution were: masculine gender (

P

= 0.004),

social isolation (

P

= 0.009); absence of mood symptoms (

P

< 0.001)

and mental automatism (

P

= 0.043).

Conclusion

Our study shows some factors associated with

schizophrenic evolution after a first episode psychosis. The iden-

tification of these factors, as well as other factors reported in the

literature is essential to allow early and adequate support, and

ensure a better social integration.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2181

EV1197

The aetiology of schizophrenia as

outlined in a treatment-resistant case

D. Vella Fondacaro

1 ,

, F . F

alzon Aquilina

2

1

Mater Dei Hospital, Ministry for Energy and Health, Mosta, Malta

2

Mount Carmel Hospital, Department of Psychiatry, Attard, Malta

Corresponding author.

Introduction

The development

of

treatment-resistant

schizophrenia in a 16-year-old Maltese girl was analyzed in

terms of its biopsychosocial model of disease.

Objectives

To highlight the presentation of treatment-resistant

schizophrenia.

To investigate the etiology of treatment-resistant schizophrenia.

Aims

To utilize the biopsychosocial model of disease in order to

investigate the aetiology of treatment-resistant schizophrenia.

To highlight the treatment modalities utilized in this case of

treatment-resistant schizophrenia.

Methods

Interviewing the patient.

Analyzing all investigations and documentation made during her

admission in an acute psychiatric hospital.

Evaluating the response to various treatment modalities.

Carrying out literature reviews.

Results

Image attached.

Conclusions

Although the aetiology of treatment-resistant

schizophrenia remains somewhat unclear even after many years

of study, the biopsychosocial model is nevertheless useful in

understanding the development of this condition. The treatment

modalities to which the patient was resistant were also identified.

Figure not available.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2182

EV1198

Clozapine and aripiprazole

combination

M.M. Vera

, C. Garay Bravo , S. Alonso Gutierrez ,

M.D.L.D. Descalzo Cabadés

Hospital universitario general de Valencia, Valencia, Spain

Corresponding author.

A 32 years old female with paranoid schizophrenia diagnosed at 20

years old, admitted for psychotic descompensation althought treat-

ment compliance. She had delusional ideas focused on her family

with suicidal behaviour and functional impairment, refractory to

different antipsychotic treatments so clozapine was initiated. Val-

proic acid was initiated too because of seizure risk. Clinically,

improvement was accomplish at these treatment doses: valproic

acid 1000mg per day; clozapine 300mg per day; and aripiprazole

150mg IM per month.

Discussion

The use of clozapine in resistant schizophrenia

patients improves functionality at the long-term and it is specially

indicated for suicidal behaviour. Recent studies show that rehospi-

talization rates for patients treated with clozapine raised 13%.

Other studies show that aripiprazole can be off label used as com-

bination therapy in these situations.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

Further readings

Csernansky JC, Schuchart EK. “Relapse rates in patients with

schizophrenia re-admissions effects of second generation antipsy-

chotics”. CNS Drugs 2002;16(7):473–83.